Develops peptide-delivered oligonucleotide therapies for people with severe neuromuscular and neurologic diseases, with current development focused on a treatment for myotonic dystrophy.
10-K for FY2025, filed Mar 4, 2026PepGen Inc. (also referred to as “PepGen,” “we,” “our” or “us”) is a clinical-stage biotechnology company advancing the next generation of…View ↗
We are currently focused on addressing the underlying cause of myotonic dystrophy type 1, or DM1, a multi-systemic neuromuscular disease…View ↗
Our EDO peptides were developed through an iterative optimization process that selected simultaneously for: biodistribution to muscle…View ↗
10-Q for Q3 FY2026, filed Nov 10, 2026
−$19.4MView ↗
Portfolio focus
The older report centered the pipeline on a Duchenne muscular dystrophy candidate and listed further Duchenne programs. The latest report centers development on a myotonic dystrophy candidate and says Duchenne research and development is being wound down.
10-K for FY2022, filed Mar 23, 2023 10-K for FY2025, filed Mar 4, 2026
Competes with Avidity Biosciences, Dyne Therapeutics, Entrada Therapeutics, Vertex Pharmaceuticals, Arrowhead Pharmaceuticals, Sarepta Therapeutics, ARTHEx Biotech, AMO Pharma, Sanofi, Astellas, Modalis, Kate Therapeutics, Arrakis Therapeutics, Rgenta Therapeutics, Alnylam Pharmaceuticals, Aro Biotherapeutics, Ionis Pharmaceuticals, and PYC Therapeutics
10-K for FY2025, filed Mar 4, 2026There are currently no approved therapies to treat the underlying cause of DM1. Product candidates currently in clinical development to…View ↗
Loading...